轻微肝性脑病早期诊断的血清生物学标志物

张钦富; 韩焕钦; 郑伟强

doi:10.3969/j.issn.1001-5256.2020.12.037

轻微肝性脑病早期诊断的血清生物学标志物

DOI: 10.3969/j.issn.1001-5256.2020.12.037

广东医科大学附属医院感染内科中心

基金项目:

广东省医学科学技术研究基金项目（A2017455）；

详细信息

中图分类号: R575.3
计量
- 文章访问数: 781
- HTML全文浏览量: 68
- PDF下载量: 92
- 被引次数: 0
出版历程
- 收稿日期: 2020-06-06
- 出版日期: 2020-12-20

Serum biomarkers for the early diagnosis of minimal hepatic encephalopathy

Infectious Diseases Center,Affiliated Hospital of Guangdong Medical University

Research funding:

摘要

摘要:
轻微肝性脑病（MHE）是指肝硬化患者出现神经心理学/神经生理学异常但认知功能正常的一种状态,在肝硬化患者中常见。早期诊断治疗MHE,可提高患者生活质量,减少意外死亡。目前主要通过心理测量肝性脑病评分诊断MHE,但其操作繁琐耗时,受年龄与教育水平等影响,临床诊断可靠性欠佳。血清生物标志物作为客观的参考指标,检测操作简便,临床容易推广。S100β、3-硝基酪氨酸、动脉血氨等潜在血清生物学标志物的特异度、敏感度及诊断价值各有优劣。现就上述血清生物学标志物进行了综述。
- 肝性脑病 /
- 生物标记 /
- 诊断
Abstract:
Minimal hepatic encephalopathy( MHE) refers to a state of neuropsychological or neurophysiological abnormality and normal cognitive function in patients with liver cirrhosis,which is commonly seen in patients with liver cirrhosis. Early diagnosis and treatment of MHE can improve the quality of life of patients and reduce accidental deaths. At present,Psychometric Hepatic Encephalopathy Score is mainly used for the diagnosis of MHE,but its operation is complicated and time-consuming and is affected by age and educational level,with unsatisfactory reliability in clinical diagnosis. Serum biomarkers are objective reference indicators with simple and convenient measurement and can easily be promoted in clinical practice. Potential serum biomarkers such as S100β,3-nitrotyrosine,and arterial blood ammonia have their own advantages and disadvantages in specificity,sensitivity,and diagnostic value. This article reviews the above-mentioned serum biomarkers.
- hepatic encephalopathy /
- biomarkers /
- diagnosis

HTML全文

参考文献(31)

[1] Chiness Society of Hepatology,Chinese Medical Association.Guidelines for the the diagnosis and management of hepatic encephalopathy in cirrhosis[J]. J Clin Hepatol,2018,34(10):2076-2089.(in Chinese)中华医学会肝病学分会．肝硬化肝性脑病诊疗指南[J]．临床肝胆病杂志，2018,34(10):2076-2089.

[2] RIDOLA L,NARDELLI S,GIOIA S,et al. Quality of life in patients with minimal hepatic encephalopathy[J]. World J Gastroenterol,2018,24(48):5446-5453.

[3] LAURIDSEN MM,THACKER LR,WHITE MB,et al. In patients with cirrhosis,driving simulator performance is associated with real-life driving[J]. Clin Gastroenterol Hepatol,2016,14(5):747-752.

[4] GUO JS. Epidemiology diagnosis and treatment of minimal hepatic encephalopathy[J]. Chin J Hepatol,2014,22(2):92-93.(in Chinese)郭津生．重视轻微型肝性脑病的流行病学及诊断与治疗[J]．中华肝脏病杂志，2014,2(22):92-93.

[5] AMPUERO J,MONTOLIU'C,SIMN-TALERO M,et al. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression[J]. J Gastroenterol Hepatol,2018,33(3):718-725.

[6] HANAI T,SHIRAKI M,WATANABE S,et al. Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan:A propensity score-matching analysis[J]. J Gastroenterol Hepatol,2019,34(10):1809-1816.

[7] FLAMM SL. Considerations for the cost-effective management of hepatic encephalopathy[J]. Am J Manag Care,2018,24(4 Suppl):s51-s61.

[8] NABI E,BAJAJ JS. Useful tests for hepatic encephalopathy in clinical practice[J]. Curr Gastroenterol Rep,2014,16(1):362.

[9] SEN J,BELLI A. S100B in neuropathologic states:The CRP of the brain?[J]. J Neurosci Res,2007,85(7):1373-1380.

[10] IKEDA Y,UMEMURA K. Analysis of reference values of serum S100B concentrations of Japanese adults[J]. Rinsho Byori,2005,53(5):395-399.

[11] ZETTERBERG H,BLENNOW K. Fluid biomarkers for mild traumatic brain injury and related conditions[J]. Nat Rev Neurol,2016,12(10):563-574.

[12] DUARTE-ROJO A,RUIZ-MARGIN A,MACIAS-RODRIGUEZ RU,et al. Clinical scenarios for the use of S100βas a marker of hepatic encephalopathy[J]. World J Gastroenterol,2016,22(17):4397-4402.

[13] KAWATA K,RUBIN LH,TAKAHAGI M,et al. Subconcussive impact-dependent increase in plasma S100βlevels in collegiate football players[J]. J Neurotrauma,2017,34(14):2254-2260.

[14] GLE爦E,IOSIFESCU DV,TURAL．Plasma Neuronal and glial markers and anterior cingulate metabolite levels in major depressive disorder:A Pilot Study[J]. Neuropsychobiology,2020,79(3):214-221.

[15] SAKDEJAYONT S,PRUPHETKAEW N,CHONGPHATTARAROT P,et al. Serum S100βas a predictor of severity and outcomes for mixed subtype acute ischaemic stroke[J]. Singapore Med J,2020,61(4):206-211

[16] GIMENEZ-GARZC,URIOS A,AGUSTA,et al. Is cognitive impairment in cirrhotic patients due to increased peroxynitrite and oxidative stress?[J]. Antioxid Redox Signal,2015,22(10):871-877.

[17] DARWISH RS,AMIRIDZE N,AARABI B. Nitrotyrosine as an oxidative stress marker:Evidence for involvement in neurologic outcome in human traumatic brain injury[J]. J Trauma,2007,63(2):439-442.

[18] MONTOLIU C,CAULI O,URIOS A,et al. 3-nitro-tyrosine as a peripheral biomarker of Minimal hepatic encephalopathy in patients with liver cirrhosis[J]. Am J Gastroenterol,2011,106(9):1629-1637.

[19] LI J,ZHAO JM,ZHANG L,et al. Diagnostic value of 3-nitrotyrosine for minimal hepatic encephalopathy[J]. J Clin Neurol,2019,32(1):25-28.(in Chinese)李洁，赵江明，张丽，等．3-硝基酪氨酸对轻微型肝性脑病的诊断价值[J]．临床神经病学杂志，2019,32(1):25-28.

[20] ATTIA MS,AL-RADADI NS. Nano optical sensor binuclear Pt-2-pyrazinecarboxylic acid-bipyridine for enhancement of the efficiency of 3-nitrotyrosine biomarker for early diagnosis of liver cirrhosis with minimal hepatic encephalopathy[J]. Biosens Bioelectron,2016,86:406-412.

[21] JAIN L,SHARMA BC,SHARMA P,et al. Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy[J]. Dig Liver Dis,2012,44(12):1027-1031.

[22] DITISHEIM S,GIOSTRA E,BURKHARD PR,et al. A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis[J]. BMC Gastroenterol,2011:134.

[23] HERR DR,CHEW WS,SATISH RL,et al. Pleotropic roles of autotaxin in the nervous system present opportunities for the development of novel therapeutics for neurological diseases[J]. Mol Neurobiol,2020,57(1):372-392.

[24] MASAGO K,KIHARA Y,YANAGIDA K,et al. Lysophosphatidic acid receptor,LPA(6),regulates endothelial bloodbrain barrier function:Implication for hepatic encephalopathy[J]. Biochem Biophys Res Commun,2018,501(4):1048-1054.

[25] SHAO X,UOJIMA H,SETSU T,et al. Usefulness of autotaxin for the complications of liver cirrhosis[J]. World J Gastroenterol,2020,26(1):97-108.

[26] LI D,ZHANG CJ. Expression and significance of lysophosphatidic acid receptor and autocrine motor factor in patients with liver cirrhosis and hepatic encephalopathy[J]. Chin Hepatol,2020,25(3):313-316.(in Chinese)李丹，张长江．溶血磷脂酸受体、自分泌运动因子在肝硬化肝性脑病患者中的表达及意义[J]．肝脏，2020,25(3):313-316.

[27] ALDRIDGE DR,TRANAH EJ,SHAWCROSS DL. Pathogenesis of hepatic encephalopathy:Role of ammonia and systemic inflammation[J]. J Clin Exp Hepatol,2015,5(Suppl 1):s7-s20.

[28] KIM YS,LEE KJ,KIM H. Serum tumour necrosis factor-αand interleukin-6 levels in Alzheimer’s disease and mild cognitive impairment[J]. Psychogeriatrics,2017,17(4):224-230.

[29] NG A,TAM WW,ZHANG MW,et al. IL-1β，IL-6,TNF-αand CRP in elderly patients with depression or Alzheimer’s disease:Systematic review and meta-analysis[J]. Sci Rep,2018,8(1):12050.

[30] CHEN JM,JIANG GX,LI QW,et al. Increased serum levels of interleukin-18,-23 and-17 in Chinese patients with Alzheimer’s disease[J]. Dement Geriatr Cogn Disord,2014,38(5-6):321-329.

[31] MONTOLIU C,PIEDRAFITA B,SERRA MA,et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy[J]. J Clin Gastroenterol,2009,43(3):272-279.

施引文献

资源附件(0)

访问统计